We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+13.75%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.01B
AUM Growth
+$76.5M
Cap. Flow
+$11.5M
Cap. Flow %
1.15%
Top 10 Hldgs %
62.46%
Holding
63
New
12
Increased
4
Reduced
12
Closed
6

Top Buys

Rank Stock Value
1
ABUS icon
Arbutus Biopharma
ABUS
+$55.6M
2
DVAX
Dynavax Technologies
DVAX
+$49.8M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$18.8M
4
ASND icon
Ascendis Pharma A/S
ASND
+$18.6M
5
OMER icon
Omeros
OMER
+$17.1M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$31.1M
2
RGLS
Regulus Therapeutics
RGLS
+$20.9M
3
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$20.2M
4
NVAX icon
Novavax
NVAX
+$14.7M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 70.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OREX
26
DELISTED
Orexigen Therapeutics, Inc.
OREX
$9.29M 0.92%
+118,623
New +$7.36M
TENX icon
27
Tenax Therapeutics
TENX
$393M
$8.71M 0.86%
83
– –
TRVN
28
DELISTED
Trevena, Inc.
TRVN
$8.64M 0.86%
2,121
-2,638
-55% -$9.68M
SCMP
29
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$7M 0.7%
+450,000
New +$6.98M
AKBA icon
30
Akebia Therapeutics
AKBA
$338M
$6.64M 0.66%
597,363
– –
FRTX
31
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$6.64M 0.66%
2,230
+261
+13% +$835K
AUPH icon
32
Aurinia Pharmaceuticals
AUPH
$1.95B
$6.56M 0.65%
1,504,776
-969,300
-39% -$3.84M
SCYX icon
33
SCYNEXIS
SCYX
$37.4M
$6.55M 0.65%
9,864
-636
-6% -$522K
CYTO
34
DELISTED
Altamira Therapeutics Ltd
CYTO
$5.03M 0.5%
12
– –
ARAV
35
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.25M 0.42%
38,545
– –
CRDF icon
36
Cardiff Oncology
CRDF
$63M
$4.05M 0.4%
+8,253
New +$3.52M
VXRT
37
DELISTED
Vaxart
VXRT
$3.23M 0.32%
127,623
+2,280
+2% +$62.8K
RMTI icon
38
Rockwell Medical
RMTI
$27.2M
$2.73M 0.27%
2,275
-4,145
-65% -$4.85M
TTOO
39
DELISTED
T2 Biosystems, Inc
TTOO
$2.14M 0.21%
28
– –
OCRX
40
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.97M 0.2%
417,476
– –
CASC
41
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.9M 0.19%
+194,294
New +$1.91M
AGIO icon
42
Agios Pharmaceuticals
AGIO
$2.08B
$1.66M 0.16%
17,600
– –
LUMO
43
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.64M 0.16%
3,333
– –
PTCT icon
44
PTC Therapeutics
PTCT
$6.18B
$1.57M 0.16%
25,800
– –
MACK
45
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.38M 0.14%
14,794
– –
RGEN icon
46
Repligen
RGEN
$6.91B
$1.37M 0.14%
45,000
– –
TSRO
47
DELISTED
TESARO, Inc.
TSRO
$1.35M 0.13%
+23,500
New +$1.11M
ALKS icon
48
Alkermes
ALKS
$8.11B
$1.17M 0.12%
19,200
– –
WGBS
49
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.16M 0.11%
51,080
-60,920
-54% -$1.21M
REGN icon
50
Regeneron Pharmaceuticals
REGN
$72.9B
$1.11M 0.11%
2,450
– –
1
2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, RA Capital Management held 63 positions worth $1.01B, up 8.2% from $930M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

RA Capital Management's Q1 2015 filing shows 12 new, 4 increased, 12 reduced and 6 closed positions. Its largest new stake was Arbutus Biopharma: 2,714,800 shares worth $47.4M. The largest sale was bluebird bio, an estimated $31.1M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 65% a quarter earlier.

  • RA Capital Management's largest Q1 2015 buy was Arbutus Biopharma: 2,714,800 shares worth $47.4M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q1 2015, an estimated $18.8M increase.
  • RA Capital Management's biggest Q1 2015 reduction was bluebird bio, cutting an estimated $31.1M.
  • RA Capital Management fully exited Forward Pharma A/S American Depositary Shares in Q1 2015, selling an estimated $20.2M.
  • RA Capital Management's ten largest holdings make up 62% of its $1.01B portfolio in Q1 2015.
  • RA Capital Management opened 12 new positions and closed 6 in Q1 2015.
  • RA Capital Management's portfolio value rose 8.2% quarter-over-quarter to $1.01B.

Based on RA Capital Management's 13F filing for Q1 2015, filed 15 May 2015.